osimertinib

Details

Key Milestones2
Call for patient/clinician input openJanuary 02, 2025
Call for patient/clinician input closedFebruary 24, 2025
Submission receivedFebruary 13, 2025
Submission acceptedFebruary 28, 2025
Review initiatedMarch 03, 2025
Draft CADTH review report(s) provided to sponsor for commentMay 20, 2025
Deadline for sponsors commentsMay 29, 2025
CDA-AMC review report(s) and responses to comments provided to sponsorJune 26, 2025
Expert committee meeting (initial)July 09, 2025
Draft recommendation issued to sponsorJuly 21, 2025
Draft recommendation posted for stakeholder feedbackJuly 31, 2025
End of feedback periodAugust 15, 2025

relugolix, estradiol, and norethindrone acetate

Details

Key Milestones2
Call for patient/clinician input openDecember 16, 2024
Call for patient/clinician input closedFebruary 18, 2025
Submission receivedFebruary 04, 2025
Submission acceptedFebruary 19, 2025
Review initiatedFebruary 20, 2025
Draft CADTH review report(s) provided to sponsor for commentMay 08, 2025
Deadline for sponsors commentsMay 20, 2025
CDA-AMC review report(s) and responses to comments provided to sponsorJune 13, 2025
Expert committee meeting (initial)June 25, 2025
Draft recommendation issued to sponsorJuly 08, 2025
Draft recommendation posted for stakeholder feedbackJuly 17, 2025
End of feedback periodJuly 31, 2025
Final recommendation issued to sponsor and drug plansAugust 13, 2025
Final recommendation posted-
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)August 27, 2025
CDA-AMC review report(s) posted-